You Position: Home > Paper

Clinical study on deanxit in the treatment of post-stroke depression

( views:348, downloads:8 )
Author:
No author available
Journal Title:
Chinese Journal of Primary Medicine and Pharmacy
Issue:
17
DOI:
10.3760/cma.j.issn.1008-6706.2011.17.002
Key Word:
氟哌噻吨/美利曲辛;抑郁症;脑卒中;Flupentixol/melitracen;Depression;Cerebrovascular accident

Abstract: Objective To evaluate the efficacy of deanxit in treatment of post-stroke depression (PSD).Methods60 patients with PSD were randomly divided into treatment group ( plus with deanxit) and control group (plus with estazolam necessarily). At the baseline and at 2 weeks,4 weeks, 8 weeks after the treatment, the efficacy was assessed with HAMD, SSS, and ADL rating scale respectively. Results After 2,4,8 weeks treatment, HAMD and SSS scores of the treatment group significantly decreased compared with the control group ( all P < 0. 01 ), and ADL scores of the treatment group increased significantly compared with the control group ( P < 0. 01 ). Conclusion Deanxit could effectively relieve depressing symptoms and neurological impairment of PSD, and clinical side effects of deanxit were less. Deanxit was suitable for acute phase and long-term maintenance therapy in PSD.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn